Login / Signup

Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan.

Satoshi YamasakiHiroatsu IidaIsao YoshidaTakuya KomenoMorio SawamuraMorio MatsumotoNaoshiro SekiguchiTerutoshi HishitaKazutaka SunamiTakeshi ShimomuraHiroshi TakatsukiShinichiro YoshidaMaki OtsukaTakeharu KatoYoshiaki KurodaTadashi OoyamaYasuhiro SuzukiKoichi OhshimaHirokazu NagaiHiromi Iwasaki
Published in: Leukemia & lymphoma (2020)
We retrospectively analyzed the risk factors for outcomes among patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS, n = 100) and angioimmunoblastic T-cell lymphoma (AITL, n = 128) who did not receive hematopoietic stem cell transplantation between 2008 and 2018. We designed a comparison of prognostic scores specifically for PTCL-NOS and AITL. The international prognostic index (IPI) was useful for investigating the risk factors associated with outcomes among transplant-ineligible patients with PTCL-NOS (Harrell's c-statistic 0.715) and AITL (c-statistic 0.615). The prognostic index for T-cell lymphoma (PIT), modified PIT, and the International Peripheral T Cell Lymphoma Project for overall survival (OS) seemed to identify separate prognostic groups, based on visual assessment of Kaplan-Meier curves. However, better c-statistics (>0.7) were only found for the IPI score for OS in PTCL-NOS. Strategies that carefully select PTCL patients with higher IPI scores may help to identify individuals suitable for novel therapies.
Keyphrases
  • nitric oxide synthase
  • quality improvement
  • healthcare
  • type diabetes
  • acute myeloid leukemia
  • nitric oxide
  • adipose tissue
  • chemotherapy induced
  • insulin resistance
  • acute care